statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alkermes plc Reports First Quarter 2024 Financial Results Alkermes plc Reports First Quarter 2024 Financial Results PR Newswire DUBLIN, May 1, 2024 First Quarter Revenues of $350.4 Million GAAP Net...

Alkermes plc Reports First Quarter 2024 Financial Results

Alkermes to Report First Quarter Financial Results on May 1, 2024 Alkermes to Report First Quarter Financial Results on May 1, 2024 PR Newswire DUBLIN, April 17, 2024 DUBLIN, April 17, 2024...

Alkermes to Report First Quarter Financial Results on May 1, 2024

Latest Ratings for ALKS
 DateFirmActionFromTo Jan 2022Cantor FitzgeraldUpgradesNeutralOverweight Dec 2021CitigroupInitiates Coverage OnNeutral Nov 2021SVB LeerinkMaintainsMarket Perform
 View...

Breaking Down Alkermes: 5 Analysts Share Their Views

Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia Alkermes Announces...

Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia

Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society Alkermes Presents Analyses From...

Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society

A closer look at one of the leaders in the global bipolar disorder treatment marketRelated Stocks: ALKS, BIIB, JNJ, PFE, ABBV, XBI, SPY...

Alkermes Innovates: Transforming Mental Health Treatment

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Alkermes management to meet with Piper Sandler

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Alkermes plc (ALKS), where a total volume of 15,015 contracts has been traded...

Noteworthy Tuesday Option Activity: ALKS, DKNG, VRT

Vanguard Group Inc. boosted its holdings in shares of Alkermes plc (NASDAQ:ALKS  Free Report) by 0.4% during the 3rd quarter, according to its most recent filing with the Securities and...

Vanguard Group Inc. Acquires 72,797 Shares of Alkermes plc (NASDAQ:ALKS)

Robert W. Baird started coverage on shares of Alkermes (NASDAQ:ALKS  Free Report) in a research note published on Tuesday morning, Marketbeat reports. The brokerage issued an outperform rating...

Alkermes (NASDAQ:ALKS) Earns Outperform Rating from Analysts at Robert W. Baird

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

Volume	2.84M
52-Wk High	$33.17
52-Wk Low	$21.66

ALKS Alkermes plc

About

Feed

News

Sentiment

Earnings

Fundamentals